Gregory Gotta, et al. SaCas9 and AsCas12a (AsCpf1) are as potent and more specific than SpCas9. Presented at Cold Spring Harbor Laboratory: Genome Engineering: Frontiers of CRISPR/Cas, October 10-13, 2019.

Dec

9

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Nov

6

Editas Medicine to Participate in Upcoming Investor Conferences

Nov

4

Editas Medicine Announces Third Quarter 2024 Results and Business Updates